Vor Biopharma (VOR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Justin Walsh from JonesTrading reiterated a Buy rating on the stock and has a $18.00 price target.
Justin Walsh has given his Buy rating due to a combination of factors that highlight the potential of Vor Biopharma’s innovative treatments. Despite the challenging economic conditions and pressures on the gene and cell therapy sector, Walsh remains optimistic about the transformative potential of VOR’s key assets, trem-cel and VCAR33, in treating relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes.
Walsh anticipates that upcoming clinical data updates will further validate the company’s scientific approach and support the planned trials, which are crucial for the company’s treatment system. Although macroeconomic factors have led to increased share dilution and a reduced price target, Walsh’s confidence in the clinical and commercial potential of VOR’s technology underpins his Buy rating.
According to TipRanks, Walsh is an analyst with an average return of -3.0% and a 27.27% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Achieve Life Sciences, and Theratechnologies.
In another report released on March 24, JMP Securities also maintained a Buy rating on the stock with a $6.00 price target.